cobas^® t 711 coagulation analyzer

Today's coagulation lab needs to meet​ clinicians' demand for fast and accurate results and cost effective solutions for a large number of routine coagulation parameters.

By delivering high processing power, seamless workflow dynamics, and unique walk away reagent management (W.A.R.M) with smart sample handling,  we answer your need for maximized workflow efficiency and reliable results. Empowering you to support the best outcome for your patients. 

High Processing Power

With the high processing power and extensive menu, the cobas t 711 coagulation analyzer enables laboratories to complete their daily testing workload fast

• High throughput
• Large on-board sample capacity
  
• High on-board reagent capacity and up to 2 weeks of on-board stability
• Increased on-board testing of up to 34,200 tests that allows loading of reagents only once per 2 weeks (for an XL workload Coag Lab)
• Flexible sample loading options and connection to automation
  Analyzers can be used in random-access or batch modes, and offer true STAT capabilities with dedicated slots for urgent samples
  

Seamless Workflow Dynamics

The cobas t 711 coagulation analyzer offers ease of use, continuous operation and maximized productivity, while ensuring operator safety and reliable results to help support better patient care. These benefits are enabled through:

• Continuous loading/unloading of samples, reagents, consumables and waste
• Flexible sample tube handling supported
  • Open and closed sample tubes on the same rack
  • Multiple tube vendors
• Sample integrity checks and full traceability of results
• e-Services available include: e-library access to download key information, Laboratory Information Systems connectivity and remote service support functionalities

Unique Walk Away Reagent Management (W.A.R.M.)

The cobas t 711 coagulation analyzer is capable of fully automated and scheduled reagent reconstitution - the ultimate enabler of continuous operation. This innovative and convenient concept minimizes user error risks, and ensures the optimized use and high quality of reagents.

• Reagent cassette concept minimizes risk of contamination and evaporation
  
• Automated scheduled reagent reconstitution and equilibration to room temperature when needed, without operator intervention
  
• Automated import of electronic data via barcode technology
  

cobas t 511 coagulation analyzer

• Throughput of 195 tests/hr
  
• Sample capacity of 75
  
• 57 reagent cassette positions for up to 34,200 tests on board
  
• Sample integrity check: HIL index, Clog detection, Automatic cuvette checks
  
• Sample loading and unloading is automated via front loading port
  

cobas t 711 coagulation analyzer

• Throughput of 390 tests/hr
  
• Sample capacity of 225
  
• 57 reagent cassette positions for up to 34,200 tests on board
  
• Sample integrity check: HIL index, Clog detection, Automatic cuvette checks
  
• Sample loading and unloading is automated via the front loading port and via the side balcony
  
• Connectivity to automation with the cobas^® 8100 automated workflow series and the cobas^® connection modules
  

Antithrombin

In vitro assay for the quantitative determination of antithrombin activity in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of antithrombin deficiency.

Anti-Xa

In vitro assay for the quantitative determination of the anti-Xa activity of unfractionated (UFH) and low molecular weight (LMWH) heparins in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the management of anti-Xa Heparin therapy.

APC Resistance

APC Resistance is a functional assay for the determination of resistance of factor Va to inactivation by activated protein C (APC) caused by the factor V Leiden mutation (FV:R506Q) in citrated plasma on indicated cobas t analyzers.

aPTT

In vitro assay, with reduced lupus sensitivity, for the determination of activated partial thromboplastin time (aPTT) in citrated plasma on the indicated cobas t analyzers. The aPTT is used to evaluate the intrinsic coagulation pathway.

aPTT Lupus

In vitro assay, with increased lupus sensitivity, for the determination of activated partial thromboplastin time (aPTT) in citrated plasma on the indicated cobas t analyzers. The aPTT is used to evaluate the intrinsic coagulation pathway.

aPTT Screen

In vitro assay for the determination of activated partial thromboplastin time (aPTT) in citrated plasma on the indicated cobas t analyzers. The aPTT is used to evaluate the intrinsic coagulation pathway.

D-Dimer

In vitro assay for the quantitative immunological determination of fibrin degradation products (D‑dimer and X‑oligomers) in human citrated plasma on the indicated cobas t analyzers. In conjunction with a non-high clinical probability assessment, a normal D‑dimer result (< 0.5 μg FEUa)/mL) is intended as an aid in the exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Fibrinogen

In vitro assay for the quantitative determination of fibrinogen (Clauss method) in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the detection of hypo- and hyperfibrinogenemia, dysfibrinogenemia and afibrinogenemia.

FII

Human plasma immunodepleted of Factor II for the quantitative determination of Factor II activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.

Free Protein S

In vitro assay for the quantitative determination of free protein S in human citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of inherited and acquired protein S deficiency.

FV

Human plasma immunodepleted of Factor V for the quantitative determination of Factor V activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.Human plasma immunodepleted of Factor II for the quantitative determination of Factor II activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.

FVII

Human plasma immunodepleted of Factor VII for the quantitative determination of Factor VII activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.

FVIII

Human plasma immunodepleted of Factor VIII for the quantitative determination of Factor VIII activity in citrated plasma, based on the activated partial thromboplastin time (aPTT) assay, on the indicated cobas t analyzers.

FX

Human plasma immunodepleted of Factor X for the quantitative determination of Factor X activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.

HIL Test

In vitro test for the semi-quantitative determination of the lipemia index, hemolysis index and icterus index in citrated plasma on cobas t systems.

Lupus S, Lupus C

In vitro assays to screen for (Lupus S) and to confirm (Lupus C) the presence of lupus anticoagulants in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of anti‑phospholipid syndrome.

PT derived Fibrinogen

The derived fibrinogen result is intended as an aid in the diagnosis of a fibrinogen deficiency.

Protein C Chromogenic

In vitro chromogenic assay for the quantitative determination of Protein C activity in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of inherited and acquired Protein C deficiencies.

PT Owren

In vitro assay for the determination of the Owrens prothrombin time in citrated plasma on the indicated cobas t analyzers. The Owrens prothrombin time is intended as an aid in the management of vitamin K antagonist therapy.

PT Rec

In vitro assay for the determination of prothrombin time and derived fibrinogen in citrated plasma on the indicated cobas t analyzers. The prothrombin time is used for evaluation of the extrinsic coagulation pathway and as an aid in the management of vitamin K antagonist therapy. The derived fibrinogen result is intended as an aid in the diagnosis of a fibrinogen deficiency.

Thrombin Time

In vitro assay for the determination of Thrombin Time (TT) in human citrated plasma on the indicated cobas t analyzers.s.

vWF Act

In vitro assay for the quantitative determination of platelet glycoprotein Ib binding activity of von Willebrand factor in human citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of inherited and acquired von Willebrand Disease (vWD).